Risk factors for early progression of diffuse low-grade glioma in adults

Background:To explore the risk factors for early progression of diffuse low-grade glioma in adults.Methods:A retrospective analysis of pathologic and clinical data of patients diagnosed with diffuse low-grade gliomas at Southwest Hospital between January 2010 and December 2014.The progression-free survival(PFS)less than 60 months was classified as the early progress group,and the PFS greater than 60 months was the control group for comparative analysis.Results:A total of 138 patients were included in this study,including 94 cases of astrocytoma and 44 cases of oligodendroglioma.There were 63 cases with 100%resection,56 cases with 90-100%resection degree,and 19 cases with resection degree<90%.The average follow-up time was 60 months,of which 80 patients progressed and 58 patients did not progress.The average progression-free survival was 61 months.The median progression-free survival was 60 months.There were 68 patients with PFS≤60 months and 70 patients with PFS>60 months.The two groups were compared for statistical analysis.In univariate analysis,there were significant differences in tumor subtype(p=0.005),range(p=0.011),volume(p=0.005),location(p=0.000),and extent of resection(p=0.000).Multifactor analysis shows tumor location(HR=4.549,95%CI:1.324-15.634,p=0.016)and tumor subtype(HR=3.347,95%CI=1.373-8.157,p=0.008),and imcomplete resection is factors influencing early progression of low-grade glioma.Conclusions:Low-grade gliomas involving deep location such as basal ganglia,inner capsule,and corpus callosum are more likely to progress early,while incomplete resection is a risk factor in early progression of astrocytoma.

Plasticity of language pathways in patients with low-grade glioma A diffusion tensor imaging study

Knowledge of the plasticity of language pathways neurosurgeons to achieve maximum resection wh n patients with low-grade glioma is important for e preserving neurological function. The current study sought to investigate changes in the ventral language pathways in patients with low-grade glioma located in regions likely to affect the dorsal language pathways. The results revealed no significant difference in fractional anisotropy values in the arcuate fasciculus between groups or between hemispheres. However, fractional anisotropy and lateralization index values in the left inferior longitudinal fasciculus and lateralization index values in the left inferior fronto-occpital fasciculus were higher in patients than in healthy subjects. These results indicate plasticity of language pathways in patients with low-grade glioma. The ventral language pathways may perform more functions in patients than in healthy subjects. As such, it is important to protect the ventral language pathways intraoperatively.

Clinical management and survival outcomes of patients withdifferent molecular subtypes of diffuse gliomas in China(2011–2017):a multicenter retrospective study from CGGA

Objective:We aimed to summarize the clinicopathological characteristics and prognostic features of various molecular subtypes of diffuse gliomas(DGs)in the Chinese population.Methods:In total,1,418 patients diagnosed with DG between 2011 and 2017 were classified into 5 molecular subtypes according to the 2016 WHO classification of central nervous system tumors.The IDH mutation status was determined by immunohistochemistry and/or DNA sequencing,and 1p/19q codeletion was detected with fluorescence in situ hybridization.The median clinical follow-up time was 1,076 days.T-tests and chi-square tests were used to compare clinicopathological characteristics.Kaplan‒Meier and Cox regression methods were used to evaluate prognostic factors.Results:Our cohort included 15.5%lower-grade gliomas,IDH-mutant and 1p/19q-codeleted(LGG-IDHm-1p/19q);18.1%lowergrade gliomas,IDH-mutant(LGG-IDHm);13.1%lower-grade gliomas,IDH-wildtype(LGG-IDHwt);36.1%glioblastoma,IDHwildtype(GBM-IDHwt);and 17.2%glioblastoma,IDH-mutant(GBM-IDHm).Approximately 63.3%of the enrolled primary gliomas,and the median overall survival times for LGG-IDHm,LGG-IDHwt,GBM-IDHwt,and GBM-IDHm subtypes were 75.97,34.47,11.57,and 15.17 months,respectively.The 5-year survival rate of LGG-IDHm-1p/19q was 76.54%.We observed a significant association between high resection rate and favorable survival outcomes across all subtypes of primary tumors.We also observed a significant role of chemotherapy in prolonging overall survival for GBM-IDHwt and GBM-IDHm,and in prolonging post-relapse survival for the 2 recurrent GBM subtypes.Conclusions:By controlling for molecular subtypes,we found that resection rate and chemotherapy were 2 prognostic factors associated with survival outcomes in a Chinese cohort with DG.

A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)

Inoperable brainstem gliomas (BSG) are among the most difficult to treat malignancies. In the intent-to-treat (ITT) population of the BT-11 study for BSG, forty patients (median age 11.2 years old) were enrolled. Antineoplastons A10 and AS2-1 (ANP) were administered intravenously daily. The median daily dose of A10 was 8.70 g/kg/day and AS2-1 was 0.32 g/kg/day. Efficacy analyses were conducted in two subgroups: recurrent pediatric diffuse intrinsic pontine glioma (RPDIPG, N?= 17) and non-diffuse intrinsic pontine glioma (NDIPG, N?= 11). This paper reports the results of the study of the efficacy and safety of ANP in patients with NDIPG. The results in the RPDIPG group were reported before;complete response (CR) was 6%, partial response (PR) 23.5%, and stable disease (SD) 17.6%. One year overall survival (OS) was 29.4%, 2 years 11.8%, and 5, 10, and 15 years 6%. In the NDIPG group, there were 36% CR and 27.5% SD. OS at 1, 5, 10, and 15 years was 82%, 73%, 62%, and 50% correspondingly. There was only one serious adverse event (9%) reported in NDIPG represented by hypokalemia, Grade 4. The results suggest that ANP shows efficacy and an acceptable tolerability profile in patients with RPDIPG and NDIPG.

Impacts of Nutlin-3a and exercise on murine double minute 2-enriched glioma treatment

Recent research has demonstrated the impact of physical activity on the prognosis of glioma patients,with evidence suggesting exercise may reduce mortality risks and aid neural regeneration.The role of the small ubiquitin-like modifier(SUMO)protein,especially post-exercise,in cancer progression,is gaining attention,as are the potential anti-cancer effects of SUMOylation.We used machine learning to create the exercise and SUMO-related gene signature(ESLRS).This signature shows how physical activity might help improve the outlook for low-grade glioma and other cancers.We demonstrated the prognostic and immunotherapeutic significance of ESLRS markers,specifically highlighting how murine double minute 2(MDM2),a component of the ESLRS,can be targeted by nutlin-3.This underscores the intricate relationship between natural compounds such as nutlin-3 and immune regulation.Using comprehensive CRISPR screening,we validated the effects of specific ESLRS genes on low-grade glioma progression.We also revealed insights into the effectiveness of Nutlin-3a as a potent MDM2 inhibitor through molecular docking and dynamic simulation.Nutlin-3a inhibited glioma cell proliferation and activated the p53 pathway.Its efficacy decreased with MDM2 overexpression,and this was reversed by Nutlin-3a or exercise.Experiments using a low-grade glioma mouse model highlighted the effect of physical activity on oxidative stress and molecular pathway regulation.Notably,both physical exercise and Nutlin-3a administration improved physical function in mice bearing tumors derived from MDM2-overexpressing cells.These results suggest the potential for Nutlin-3a,an MDM2 inhibitor,with physical exercise as a therapeutic approach for glioma management.Our research also supports the use of natural products for therapy and sheds light on the interaction of exercise,natural products,and immune regulation in cancer treatment.

Focus on current and emerging treatment options for glioma:A comprehensive review

This comprehensive review delves into the current updates and challenges associated with the management of low-grade gliomas(LGG),the predominant primary tumors in the central nervous system.With a general incidence rate of 5.81 per 100000,gliomas pose a significant global concern,necessitating advancements in treatment techniques to reduce mortality and morbidity.This review places a particular focus on immunotherapies,discussing promising agents such as Zotiraciclib and Lerapolturev.Zotiraciclib,a CDK9 inhibitor,has demonstrated efficacy in glioblastoma treatment in preclinical and clinical studies,showing its potential as a therapeutic breakthrough.Lerapolturev,a viral immunotherapy,induces inflammation in glioblastoma and displays positive outcomes in both adult and pediatric patients.Exploration of immunotherapy extends to Pembrolizumab,Nivolumab,and Entrectinib,revealing the challenges and variabilities in patient responses.Despite promising preclinical data,the monoclonal antibody Depatuxizumab has proven ineffective in glioblastoma treatment,emphasizing the critical need to understand resistance mechanisms.The review also covers the success of radiation therapy in pediatric LGG,with evolving techniques,such as proton therapy,showing potential improvements in patient quality of life.Surgical treatment is discussed in the context of achieving a balance between preserving the patient’s quality of life and attaining gross total resection,with the extent of surgical resection significantly influencing the survival outcomes.In addition to advancements in cancer vaccine development,this review highlights the evolving landscape of LGG treatment,emphasizing a shift toward personalized and targeted therapies.Ongoing research is essential for refining strategies and enhancing outcomes in the management of LGG.

Adaptability of language-related brain network in a low-grade glioma patient

Because functional magnetic resonance imaging can be used for dynamic observation of functional cortical changes after brain injuries, we followed up functional magnetic resonance imaging manifestations of a language-related brain network in a low-grade glioma patient. Disease progression and therapy during a 3-year period were followed up at different time points： before and after reoperation, after radiation therapy, and 1 year after irradiation. During the whole 3-year follow-up period, the patient exhibited no neurological deficits while functional magnetic resonance imaging revealed different topologies of the language-related brain network. During disease progression and after irradiation, the language-related brain network was extended or completely transferred to the nondominant （right） hemisphere. In addition, after reoperation and 1 year after irradiation, language areas were primarily found in the language dominant （left） hemisphere. Our results suggest a high level of adaptability of the language-related cortical network of the bilateral hemispheres in this low-grade glioma patient.

ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma

PURPOSE:This study was conducted to investigate the incidence of ERBB1 amplification and overexpression in samples of diffusely infiltrative (WHO grades Ⅱ-Ⅳ) pediatric brain stem glioma (BSG) and determine the relationship of these abnormalities to expression and mutation of TP53 and tumor grade. Experimental Design: After central pathology review, the incidence of ERBB1 amplification and overexpression was determined in 28 samples (18 surgical biopsy and 10 postmortem specimens) of BSG using quantitative PCR and immunohistochemistry,

The surgical treatment of low-grade glioma with secondary epilepsy

Objective To explore the methods of surgical treatment of low-grade glioma with secondary epilepsy. Methods Video-EEG, magnetoencephalography (MEG) were performed to localizate the epileptogenic zone and domain in 13 patients,and stereotactic technology ,ultrasoumd,electrocorticogram (EcoG) were combined

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)

Nonresectable Low-Grade Astrocytomas (LGA) can compromise function and threaten life. For the majority of patients, the most appropriate strategy is initial chemotherapy followed by Radiation Therapy (RT). Since curative treatment is not available for most of these patients, it is reasonable to conduct clinical studies to evaluate new agents. This Phase II study evaluates efficacy and safety of Antineoplastons A10 and AS2-1 (ANP) in LGA. Sixteen children diagnosed with LGA were treated. They included 12 males and 4 females, ages 1.6 - 17.4 years (median 10.6). Efficacy was evaluated in 16 patients. The majority of patients were previously treated, but 1 patient had stereotactic biopsy only. Out of the remaining 15 patients, 6 patients received chemotherapy, and 7 patients had surgery, and 2 patients received RT and chemotherapy after surgery. The patients received treatment with ANP administered daily every 4 hours (median dose of A10 was 7.71 g/kg/d and AS2-1 was 0.26 g/kg/d) until objective response or stable disease was documented and for 8 months thereafter. The duration of ANP IV ranged from 1.4 to 286 weeks with a median of 83 weeks. A complete response was documented in 25.0%, partial response in 12.5%, and stable disease in 37.5%. Overall survival was 67.7% at 5 years, and 54.2% at 10 and 15 years. Progression-free survival was 48.1%, 34.4% and 34.4% at 5, 10, and 15 years respectively. The treatment was associated with grade 3 or grade 4 Adverse Drug Experiences (ADE) in 6 patients. There were two hypernatremias of grade 4 (12%). Grade 3 ADE included urinary frequency (6%), fatigue (6%) and hypernatremia (6%). There were no chronic toxicities, and there was a high quality of survival. ANP shows efficacy with a very good toxicity profile in this cohort of children with low-grade astrocytoma.

Diffusive modelling of glioma evolution: a review

Gliomas, the most aggressive form of brain cancer, are known for their widespread invasion into the tissue near the tumor lesion. Exponential models, which have been widely used in other types of cancers, cannot be used for the simulation of tumor growth, due to the diffusive behavior of glioma. Diffusive models that have been proposed in the last two decades seem to better approximate the expansion of gliomas. This paper covers the history of glioma diffusive modelling, starting from the simplified initial model in 90s and describing how this have been enriched to take into account heterogenous brain tissue, anisotropic migration of glioma cells and adjustable proliferation rates. Especially, adjustable proliferation rates are very important for modelling therapy plans and personalising therapy to different patients.

Exploratory therapy for brainstem gliomas

Brainstem gliomas comprise both slow-growing and highly aggressive tumors,the latter carrying a dismal prognosis of approximately 10 months in children.Given their common locations along the brainstem,they are often not amenable to surgical resection.There are currently a host of exploratory therapies under investigation ranging from immunotherapy,small molecular inhibitors,epigenetic-modifying agents,and radiation protocols to combat these difficult-to-treat tumors.Recent discoveries highlighting the role of H3 histone mutations in diffuse midline glioma oncogenesis have yielded a variety of new targetable antigens and aberrant signaling pathways.Although many of these studies have shown promise in terms of inhibiting tumor growth and disease progression,results to date have been modest in their ability to translate into meaningful clinical benefit.This review will serve as an updated report on the current state of literature concerning pre-clinical and clinical therapies being investigated for brainstem glioma.In addition,this review will serve as a guide for clinicians as we review the evolving nomenclature of brainstem gliomas,commonly presenting symptoms,diagnostic tools,and standard therapies.

磁共振FSE/MDME序列联合DWI预测胶质瘤病理组织学分级及增殖活性的研究

目的:探讨快速自旋回波(FSE)/多延迟饱和多回波(MDME)联合弥散加权成像(diffusion-weighted imaging,DWI)预测胶质瘤病理组织学分级,并进一步分析与增殖活性的关系,旨在为早期识别高级别及高增殖活性人群提供更多有价值信息。方法:回顾性纳入2018年01月至2023年01月于我院行手术治疗并经病理组织学检查证实为胶质瘤患者137例,根据病理组织学分级情况分为高级别组(82例)和低级别组(55例);比较两组基线临床资料及磁共振影像学定量分析指标,FSE/MDME联合DWI磁共振用于胶质瘤病理组织学分级预测临床效能分析。结果:两组基线临床资料比较差异无统计学意义(P>0.05);低级别组T1值和质子密度均显著低于高级别组(P<0.05);低级别组表观弥散系数显著高于高级别组(P<0.05);两组T2值比较差异无统计学意义(P>0.05)。T1值、质子密度及表观弥散系数均可用于胶质瘤病理组织学分级预测,单一指标中表观弥散系数预测AUC显著高于T1值及质子密度,同时三者联合预测效能优于三者单用(P<0.05)。胶质瘤患者表观弥散系数与Ki-67阳性细胞比例呈负相关,而T1值和质子密度与Ki-67阳性细胞比例呈正相关(P<0.05),但T2值则与Ki-67阳性细胞比例无相关性(P>0.05)。结论:FSE/MDME联合DWI磁共振可用于胶质瘤病理组织学分级预测,且T1值、质子密度及表观弥散系数三者联合预测效能最佳;同时上述磁共振定量分析指标与胶质瘤组织细胞增殖活性有关。

多模态MRI影像组学及深度学习在胶质瘤诊疗中的研究进展

弥漫性胶质瘤是最常见的颅脑原发恶性肿瘤,术前精准分级、分子分型预测等对于制订适当的治疗策略和预测生存率具有至关重要的作用。影像组学使用高级特征分析从医学图像中提取数据并构建预测模型,捕捉病变微小的变化,从而提高临床诊断、评估预后和预测治疗反应的准确性。深度学习(deep learning, DL)可以从大量原始数据中自动学习和提取多层特征,而不是手工提取的浅层特征,由于DL已被充分证明能够准确地找到非常深入和抽象的特征,这使其成为医学图像分析领域中广泛研究的课题。随着计算能力的进步,基于DL的人工智能已经彻底改变了各个领域。本研究基于多模态MRI影像组学与DL在胶质瘤术前分级、分子分型、生存预测及治疗评价中的最新研究进行综述,以期为胶质瘤患者提供精准诊疗。

弥漫性胶质瘤瘤周水肿组织BMAL1的表达及其临床意义

目的探讨弥漫性胶质瘤瘤周水肿组织脑和肌肉ARNT样蛋白1(BMAL1)的表达及其临床意义。方法选取2021年6月至2023年1月手术切除的64例弥漫性胶质瘤瘤周水肿组织,免疫组化法检测瘤周水肿组织BMAL1表达;术前进行脑MRI检查,计算水肿指数评估瘤周水肿程度。结果64例均伴有瘤周水肿,其中轻度水肿20例,中度水肿9例,重度水肿35例;瘤周水肿组织BMAL1高表达39例,低表达25例。瘤周水肿组织BMAL1免疫组化染色评分与水肿指数呈明显正相关(r=0.408;95%CI 0.179~0.594;P<0.001)。多因素logistic回归分析显示,BMAL1高表达是弥漫性胶质瘤并发重度瘤周水肿的独立影响因素(OR=5.558;95%CI 1.897~8.467;P<0.001)。结论弥漫性胶质瘤瘤周水肿组织BMAL1表达水平与瘤周水肿程度呈正相关,提示BMAL1可能参与弥漫性胶质瘤瘤周水肿的发生、进展。

DKI及DTI在鉴别诊断低级别胶质瘤与脑炎中的价值

目的评估MR扩散峰度成像(diffusion kurtosis imaging,DKI)及扩散张量成像(diffusion-tensor imaging,DTI)在鉴别低级别胶质瘤与脑炎中的价值。材料与方法回顾性分析58例低级别胶质瘤或脑炎患者的影像学资料,所有患者在术前或保守治疗前均行MRI常规序列及DKI序列扫描。用NeuDiLab软件处理DKI图像,获得基于DKI模型的平均峰度(mean kurtosis,MK)、轴向扩散峰度(axial kurtosis,AK)和径向扩散峰度(radial kurtosis,RK)以及基于DTI模型的平均扩散系数(mean diffusivity,MD)、轴向扩散系数(axial diffusivity,AD)、径向扩散系数(radial diffusivity,RD)和各向异性分数(fractional anisotropy,FA)参数图及b=0 s/mm2的扩散图像(B0)。用ITK-SNAP软件在B0图像上手动勾画肿瘤的感兴趣容积(volume of interest,VOI),将其配准到其他参数图上。用FAE软件提取各参数图的平均值。根据病理检查或脑脊液检查结果将患者分为胶质瘤组和脑炎组。采用卡方检验、独立样本t检验及Mann-Whitney U检验比较两组患者的一般资料、常规MRI表现及扩散参数的差异。计算Cohen’s d值评估各扩散参数的效应量。绘制受试者工作特征(receiver operating characteristic,ROC)曲线,计算曲线下面积(area under the curve,AUC)、敏感度、特异度和准确度,并用De Long检验比较各参数的鉴别诊断效能。结果共51例患者被纳入研究,包括29例低级别胶质瘤患者、22例脑炎病变患者。RK鉴别诊断脑炎组低级别胶质瘤的表现最好,AUC为0.878,当阈值取0.662时,其敏感度为72.7%,特异度为89.7%。De Long检验显示DKI模型的诊断表现显著优于DTI模型。结论DKI序列有助于鉴别诊断低级别胶质瘤与脑炎。

儿童弥漫性中线胶质瘤伴H3K27变异型102例临床病理特征

目的 探讨儿童弥漫性中线胶质瘤(diffuse midline gliomas, DMG)伴H3K27变异型的临床病理特点和分子学特征。方法 收集102例DMG伴H3K27变异型患者临床资料,采用HE、免疫组化EnVision两步法染色,应用Sanger测序法行分子检测,分析其临床病理特征并复习相关文献。结果 患者发病年龄1~14岁,中位年龄7岁。发病部位:脑干83例(81.4%),非脑干如丘脑、基底节和松果体等19例(18.6%)。临床表现主要为头晕、头痛和步态不稳等。MRI示T1低信号或等信号,T2高信号。组织学示高级别64例(62.7%),低级别38例(37.3%)。免疫表型:H3K27me3表达降低或缺失(100%,81/81),表达H3K27M(98%,100/102)、EZHIP(2%,2/102)、BRAF V600E(2.2%,2/89);p53突变型占53.6%(52/97);ATRX失表达(19.1%,18/94);IDH1不表达(100%,89/89)。分子检测示BRAF突变占1.7%(1/59);EGFR突变占9.1%(1/11)。结论 儿童DMG伴H3K27变异型好发于脑干,组织学以高级别为主,H3K27me3染色呈不同程度表达缺失,分子变异包括H3K27M突变、EZHIP过表达和EGFR突变。

多模态MRI功能成像在脑胶质瘤术后复发与治疗后反应评估中的价值

目的比较MR扩散加权成像(DWI)、三维动脉自旋标记成像(3D ASL)在鉴别脑胶质瘤术后复发与治疗后反应的诊断价值,为临床精准治疗提供客观依据。方法回顾分析我院2019年1月-2023年7月间行脑胶质瘤手术,术后放化疗1月以上,随访过程中首次出现异常强化病灶者47例,进行MRI平扫、DWI、3D ASL、增强扫描检查,分别测量DWI的表观扩散系数(ADC)值和相对ADC(rADC)值、3D ASL的血流动力学参数CBF值和相对CBF(rCBF)值。利用两样本t检验、受试者工作特征曲线(ROC)分析来评估研究参数在鉴别治疗后反应方面的诊断与胶质瘤术后复发效能。结果47例患者中,30例为脑胶质瘤复发,17例为治疗后反应,1.脑胶质瘤复发强化区CBF值为(119.16±18.58)mL/100g/1min,治疗后反应区的CBF值为(72.06±22.77)mL/100g/1min,差异有统计学意义(P<0.05);脑胶质瘤复发强化区rCBF值为3.56±1.13,放射损伤区的rCBF值为1.18±0.39,差异有统计学意义(P<0.05);2.ADC在脑胶质瘤复发和治疗后反应之间没有明显差异(P=0.235);rADC(P<0.05)在脑胶质瘤复发和治疗后反应之间差异有统计学意义;3.3D ASL(rCBF)诊断脑胶质瘤复发曲线下面积约0.971,ADC诊断脑胶质瘤复发曲线下面积约为0.675。结论与DWI序列相比,3D ASL成像技术在鉴别胶质瘤复发和治疗后反应方面显示出更好的诊断效能。

MRI用于胶质瘤神经重塑的研究进展

胶质瘤是成人最常见的恶性脑肿瘤,复发率高且预后极差。神经重塑是大脑在胶质瘤生长中发生的复杂而精密的适应性反应,深入理解大脑的神经重塑对于改善胶质瘤病人生活质量,延长病人生存期具有重要意义。利用高分辨三维T1加权成像(3D T1WI)、扩散张量成像(DTI)及血氧水平依赖功能MRI(BOLD-fMRI)等技术,同时结合先进的影像分析方法可以探索胶质瘤病人结构和功能方面的可塑性及其相关机制。就不同MRI技术对胶质瘤病人结构和功能重塑的研究进行综述,并展望未来的研究方向。

基于DWI的分形维数评价3D打印技术对胶质瘤术后临床疗效的价值

目的使用基于弥散加权成像(diffusion weighted imaging,DWI)的分形维数(fractal dimension,FD)评价个性化3D打印技术是否可以提高手术治疗胶质瘤患者的临床疗效。材料与方法回顾性分析2018年1月至2023年1月我院经病理证实的136例胶质瘤患者病例,其中32例为试验组,术前使用了个性化3D打印技术;其余患者为对照组,进行常规开颅手术。在术后一周DWI图上手动勾画术区周围边界,绘制二值图后测量FD。使用FD中位数对对照组进行分组,比较对照组中高FD和低FD患者的手术情况、疼痛程度、神经缺损程度、预后、日常生活能力是否存在差异;探究个性化3D打印技术是否会影响水肿创面的FD,以及是否会进一步提高患者临床疗效。结果高FD组的疼痛程度(t=−13.228,P<0.001)、神经缺损程度(t=−2.627,P=0.008)高于低FD组,日常生活能力(t=4.821,P<0.001)及预后(t=−3.058,P=0.003)较低FD组差。受试者工作特征(receiver operating characteristic,ROC)曲线结果显示FD能对患者上述四项评分的高低进行有效区分,术前使用个性化3D打印技术可使得患者水肿带FD下降,减轻神经缺损程度并提高日常生活能力,但对改善预后及术区疼痛效果不明显。结论个性化3D打印技术可以有效降低患者术区创面水肿带的FD,减轻神经损伤,值得临床应用。